Mechanical Circulatory Support on Coronary Artery Bypass Grafting for Advanced Ischemic Cardiomyopathy: State of the

Erik J Orozco-Hernandez1, James E Davies1, Sasha Anne Still1

  • 1Division of Cardiothoracic Surgery, Department of Cardiac Surgery, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

Insights

Mechanical circulatory support (MCS) can aid high-risk patients undergoing coronary artery bypass grafting (CABG) for ischemic cardiomyopathy. Careful selection and timing of MCS are crucial for optimizing outcomes and mitigating risks.

Area of Science:

  • Cardiology
  • Cardiac Surgery
  • Mechanical Circulatory Support

Background:

  • Ischemic cardiomyopathy involves coronary artery disease and left ventricular dysfunction (ejection fraction ≤ 40%).
  • Myocardial tissue in ischemic cardiomyopathy is heterogeneous, comprising normal, stunned, hibernating, and scarred regions.
  • Isolated assessments of myocardial viability and ischemia are insufficient for guiding coronary artery bypass grafting (CABG) decisions.

Purpose of the Study:

  • To review indications and criteria for mechanical circulatory support (MCS) in advanced ischemic cardiomyopathy patients.
  • To discuss various MCS devices for preoperative or intraoperative support.
  • To examine technical considerations, advantages, disadvantages, and complications of MCS.

Main Methods:

  • Review of current literature on mechanical circulatory support in ischemic cardiomyopathy.
  • Analysis of factors influencing the decision for MCS, including clinical presentation, viability, hemodynamics, and imaging.
  • Evaluation of preoperative optimization strategies involving MCS.

Main Results:

  • Preoperative MCS can mitigate the impact of cardiopulmonary bypass, preserve end-organ perfusion, and reduce vasopressor needs.
  • Integrating anatomical, morphological, functional, and hemodynamic data aids precise MCS selection and timing.
  • The risk-benefit ratio of MCS requires careful consideration due to potential complications.

Conclusions:

  • Judicious use of MCS can enhance CABG safety in high-risk patients with ischemic cardiomyopathy.
  • Further robust, long-term prospective studies are needed to establish the definitive clinical impact of MCS.
  • Optimizing MCS selection and timing is critical for improving outcomes in this patient population.